411 related articles for article (PubMed ID: 29522918)
1. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
Gurung AB; Mayengbam B; Bhattacharjee A
Comput Biol Chem; 2018 Jun; 74():1-11. PubMed ID: 29522918
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
Karami L; Saboury AA; Rezaee E; Tabatabai SA
Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
[TBL] [Abstract][Full Text] [Related]
3. Discovery of phthalimide derivatives as novel inhibitors of a soluble epoxide hydrolase.
Mahlooji I; Shokri M; Manoochehri R; Mahboubi-Rabbani M; Rezaee E; Tabatabai SA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000052. PubMed ID: 32484272
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Zhang W; Koerner IP; Noppens R; Grafe M; Tsai HJ; Morisseau C; Luria A; Hammock BD; Falck JR; Alkayed NJ
J Cereb Blood Flow Metab; 2007 Dec; 27(12):1931-40. PubMed ID: 17440491
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
[TBL] [Abstract][Full Text] [Related]
7. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
Diani-Moore S; Ma Y; Gross SS; Rifkind AB
Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
Revermann M; Barbosa-Sicard E; Dony E; Schermuly RT; Morisseau C; Geisslinger G; Fleming I; Hammock BD; Brandes RP
J Hypertens; 2009 Feb; 27(2):322-31. PubMed ID: 19226702
[TBL] [Abstract][Full Text] [Related]
9. Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase.
Manickam M; Pillaiyar T; Boggu P; Venkateswararao E; Jalani HB; Kim ND; Lee SK; Jeon JS; Kim SK; Jung SH
Eur J Med Chem; 2016 Jul; 117():113-24. PubMed ID: 27092411
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
[TBL] [Abstract][Full Text] [Related]
11. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
[TBL] [Abstract][Full Text] [Related]
12. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
Pillarisetti S; Khanna I
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
[TBL] [Abstract][Full Text] [Related]
13. Novel amide derivatives of 3-phenylglutaric acid as potent soluble epoxide hydrolase inhibitors.
Rezaee E; Amrolah SM; Nazari M; Tabatabai SA
Mol Divers; 2021 Feb; 25(1):45-53. PubMed ID: 31873869
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.
Sun CP; Zhang XY; Morisseau C; Hwang SH; Zhang ZJ; Hammock BD; Ma XC
J Med Chem; 2021 Jan; 64(1):184-215. PubMed ID: 33369424
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography.
Amano Y; Yamaguchi T; Tanabe E
Bioorg Med Chem; 2014 Apr; 22(8):2427-34. PubMed ID: 24656800
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
Koeners MP; Wesseling S; Ulu A; Sepúlveda RL; Morisseau C; Braam B; Hammock BD; Joles JA
Am J Physiol Endocrinol Metab; 2011 Apr; 300(4):E691-8. PubMed ID: 21266668
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
18. Soluble epoxide hydrolase: a new target for cardioprotection.
Gross GJ; Nithipatikom K
Curr Opin Investig Drugs; 2009 Mar; 10(3):253-8. PubMed ID: 19333883
[TBL] [Abstract][Full Text] [Related]
19. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.
Kim IH; Nishi K; Tsai HJ; Bradford T; Koda Y; Watanabe T; Morisseau C; Blanchfield J; Toth I; Hammock BD
Bioorg Med Chem; 2007 Jan; 15(1):312-23. PubMed ID: 17046265
[TBL] [Abstract][Full Text] [Related]
20. The weakening effect of soluble epoxide hydrolase inhibitor AUDA on febrile response to lipopolysaccharide and turpentine in rat.
Piotrowski J; Jędrzejewski T; Pawlikowska M; Pacuła AJ; Ścianowski J; Kozak W
J Physiol Biochem; 2017 Nov; 73(4):551-560. PubMed ID: 28741242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
